393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers

• Naomi Hunder,
• Celine Jacquemont,
• Sarina Piha-Paul,
• Samuel Klempner,
• Valerie Odegard,
• John Strickler,
• Lindsey Gourley,
• Vinona Bhatia

Affiliations

Naomi Hunder

Aff12 grid.419971.3Formerly of ZymoGenetics (Bristol-Myers Squibb) Seattle WA USA

Celine Jacquemont

Aff5 Phenopath Seattle WA USA

Sarina Piha-Paul

1MD Anderson Cancer Center, Houston, TX, USA

Samuel Klempner

1Massachusetts General Hospital, Boston, MA, USA

Valerie Odegard

5Silverback Therapeutics, Inc., Seattle, WA, USA

John Strickler

2Duke University School of Medicine, Durham, NC, USA

Lindsey Gourley

3Silverback Therapeutics, Inc., Seattle, WA, USA

Vinona Bhatia

3Silverback Therapeutics, Inc., Seattle, WA, USA